Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBI-1501
- Development stage
- Phase 1
- Lead developer
- VBI Vaccines
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular Injection
01
Overview
VBI-1501 is a prophylactic vaccine candidate developed to prevent cytomegalovirus (CMV) infection. It utilizes proprietary enveloped virus-like particle (eVLP) technology to present a modified form of the glycoprotein B (gB) found on CMV. The vaccine is designed to induce neutralizing antibody responses against multiple cell types infected by CMV, including fibroblast and epithelial cells. In Phase 1 clinical trials, VBI-1501 demonstrated safety and immunogenicity at all tested doses, with the highest dose eliciting protective neutralizing antibodies in 100% of subjects for fibroblast cell infection and in 31% for epithelial cell infection after three vaccinations. The vaccine is administered intramuscularly and continues development as a potential preventive measure against congenital CMV infection[1][2][3][6][7].
- Other names
- VBI 1501AVBI1501AVBI-1501ACMV Vaccine (VBI-1501)
02
Targets
gB (Human cytomegalovirus glycoprotein B)
Beyond the preview
Go deeper on VBI-1501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBI-1501.